Addressing Racial and Sociodemographic Inequities in Hepatitis C Management

Overview

Treatment rates for hepatitis C virus (HCV) remain low across insurance types in urban settings despite progressive policies. Medicaid and uninsured populations experience the lowest treatment rates, highlighting persistent disparities even after removal of prior authorization restrictions in some programs.

Background

Hepatitis C virus infection is a significant public health concern with substantial morbidity, mortality, and economic burden. Urban academic centers report low treatment rates, particularly among Medicaid and uninsured populations. Prior authorization requirements have been identified as major barriers to timely HCV treatment initiation. Recent policy changes, such as removal of prior authorization in Medicaid programs, aim to improve access but disparities persist.

Data Highlights

Key Findings

• Only 26.5% of people with HCV were treated in an urban academic center, with treatment rates varying by insurance: Medicare 55%, private commercial 48%, Medicaid 32%, no insurance 21%.
• In Los Angeles County, 69% of people with HCV remain untreated, including 66% of those with commercial insurance.
• Removal of prior authorization restrictions in California Medicaid (Medi-Cal) in 2024 is a critical step but has not fully resolved treatment disparities.
• Homelessness and substance use disorder are significant predictors of low HCV treatment rates, disproportionately affecting Medicaid enrollees.
• Prior authorization remains a major barrier in private and other public insurance plans, causing treatment delays and loss to follow-up.
• Untreated HCV leads to increased inpatient and emergency department visits and contributes to a $10 billion annual economic burden in the U.S.

Clinical Implications

Clinicians should be aware that despite policy advances, many patients—especially those insured by Medicaid or uninsured—face barriers to HCV treatment. Addressing social determinants such as housing instability and substance use is essential. Advocacy for elimination of prior authorization across all insurance types can facilitate timely treatment initiation and reduce long-term complications.

Conclusion

Removing prior authorization restrictions is necessary but insufficient alone to achieve equitable hepatitis C elimination. Comprehensive strategies addressing social and systemic barriers are required to improve treatment uptake and reduce disparities.

References

1. Elnaiem et al. 2023 -- Hepatitis C Treatment Rates and Insurance Type
2. Project HCV Connect, Los Angeles County Surveillance Registry
3. California Medicaid Prior Authorization Policy Update 2024
4. California Housing Instability and Medicaid Enrollment Data
5. Substance Use Disorder and Medi-Cal Enrollment Statistics
6. Provider Perspectives on HCV Treatment Barriers Study
7. Economic Burden of HCV-Related Liver Disease in the U.S.